Guaresti G, Clausen M, Espínola N, Graciano A, Guarnieri L, Perelli L, et al. Childhood obesity and sugar-sweetened beverages in Río Negro: Burden of disease and expected impact of Law no. 27642 on the Promotion of Healthy Eating. Arch Argent Pediatr. 2024;122(6):e202310109.
Greeshma J, Mini GK, Marthanda Pillai A, Irazola V. Cardiovascular disease risk factor prevalence among police officials: findings from a cross-sectional study in Kerala, India. J Occup Health. 2024;66(1).
González-Marrón A, Casarini A. Consumo de tabaco en Costa Rica: ¿está el país preparado para el “fin del juego”? Rev Panam Salud Publica. 2024;48:e8.
Consumo de tabaco en Costa Rica: ¿está el país preparado para el “fin del juego”? Ver más »
Goldstein CE, Marouf Y, Johri M, Shaw JF, Sergeant A, Nicholls SG, et al. Systematic scoping review of cluster randomised trials conducted exclusively in low-income and middle-income countries between 2017 and 2022. BMJ Open. 2024;14(9):e087724.
Gausman J, Kenu E, Adanu R, Bandoh DAB, Berrueta M, Chakraborty S, et al. Validating the indicator "maternal death review coverage" to improve maternal mortality data: A retrospective analysis of district, facility, and individual medical record data. PLoS One. 2024;19(5):e0303028.
Garcia PJ, Saavedra J, Espinoza-Pajuelo L, Garcia-Terron FA, Garzon X, Rubinstein A, et al. Why Latin America needs a regional Centre for Disease Control and Prevention. Lancet. 2024;403(10446):2763-5.
Why Latin America needs a regional Centre for Disease Control and Prevention Ver más »
Francoeur C, Alcamo AM, Robertson CL, Wainwright MS, Roa JD, Lovett ME, et al. Severe Pediatric Neurological Manifestations With SARS-CoV-2 or MIS-C Hospitalization and New Morbidity. JAMA Netw Open. 2024;7(6):e2414122.
Feifer D, Merz AF, Avery M, Tsuchiyose E, Eche-Ugwu IJ, Awofeso O, et al. Parent Views on Parent and Child-reported Outcomes in Pediatric Advanced Cancer: A Qualitative Study. J Pain Symptom Manage. 2024;69(2):e131-e8.
Espinola N, Secco A, Balan D, Kanevsky D, Calvi G, Morisset P, et al. Budget impact of upadacitinib in patients with moderate to severe rheumatoid arthritis in Argentina. Rev Peru Med Exp Salud Publica. 2024;41(2):129-39.
Espinola N, Rodríguez Cairoli F, Rojas-Roque C, Luna PC, Kanevsky D, Migliazza V, et al. Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina. Expert Rev Pharmacoecon Outcomes Res. 2024;25(1):101-11.
